NCT01635647View on ClinicalTrials.gov

A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

730

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions
Malaria
Interventions
BIOLOGICAL

ChAd63 ME-TRAP and MVA ME-TRAP

ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation

BIOLOGICAL

Rabies vaccine

Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab

Trial Locations (1)

BP 2208

Centre for Clinical Vaccinology and 1. Centre National de Recherche et de Formation sur le Paludisme (CNRFP)/ Unité de Recherche Clinique de Banfora (URC-B), Ouagadougou

All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

University of Oxford

OTHER

NCT01635647 - A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso | Biotech Hunter | Biotech Hunter